2-Ethylsulfanyl-6-(hydroxymethyl)oxane-3,4,5-triol | 7473-36-1

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Ethylsulfanyl-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 7473-36-1
• 化学式: C₈H₁₆O₅S
• 分子量: 224.28
• InChiKey: CHAHFVCHPSPXOE-UHFFFAOYSA-N

物化性质

• 熔点：
  87-89°C
• 沸点：
  440.8±45.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

制备方法与用途

用途：硫代葡萄糖苷具有潜在的抗肿瘤作用。

文献信息

• Preparation of Thiosugars and Their Use
  申请人：Davis Benjamin Guy

  公开号：US20090176970A1

  公开（公告）日：2009-07-09

  A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents an O- or S-protecting group(s), to Birch reduction.

  一种制备由糖硫代糖（Saccharide-S-H）表示的硫代糖的方法，其中糖代表至少4个糖单元，包括将具有以下结构的相应化合物（P）糖硫代糖（P）进行桦还原：（P）糖硫代糖（P），其中（P）代表一个或多个O-或S-保护基。
• Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonas
  申请人：Magnani L. John

  公开号：US20070037775A1

  公开（公告）日：2007-02-15

  Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.

  提供与铜绿假单胞菌相关的组合物和方法。这些组合物和方法可用于诊断和治疗涉及铜绿假单胞菌感染的医疗状况。这些感染包括囊性纤维化患者肺部中的铜绿假单胞菌。在目前的方法中有用的化合物可以与治疗剂结合使用，或者可以与治疗剂连接。通过阻止定植、抑制毒力因子、阻止生长或杀死细菌可以抑制铜绿假单胞菌。
• PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY
  申请人：MAGNANI John L.

  公开号：US20090253646A1

  公开（公告）日：2009-10-08

  Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.

  提供了用于治疗与之相关的疾病或并发症的化合物、组合物和方法，其中选择素起作用。更具体地描述了特定的糖类拟态剂及其用途。例如，描述了利用特定的糖类拟态剂治疗镰状细胞病或涉及选择素的癌症，或与任一疾病相关的并发症。
• ANTI-EPILEPTOGENIC AGENTS
  申请人：Magnani John L.

  公开号：US20130261070A1

  公开（公告）日：2013-10-03

  Methods and medicaments therefor are provided for altering an epileptic syndrome in an individual. Methods and medicaments therefor are also provided for preventing an epileptic syndrome in an individual at risk for developing an epileptic syndrome. More specifically, the use of particular glycomimetics for the treatment or prevention is described.

  本发明提供了用于改变个体癫痫综合症的方法和药物。本发明还提供了用于预防个体癫痫综合症的方法和药物，该个体处于发展癫痫综合症的风险之中。更具体地，本发明描述了用于治疗或预防的特定糖类似物的使用。
• Lectin-directed prodrug delivery system
  申请人：Davis Guy Benjamin

  公开号：US20070253942A1

  公开（公告）日：2007-11-01

  The invention provides a kit for lectin-directed prodrug delivery comprising a prodrug and a lectin-directed glycoconjugate, wherein the glycoconjugate is adapted to cleave the prodrug and thereby release the drug. The glycoconjugate generally comprises an enzyme conjugated to a carbohydrate moiety which binds to a lectin. The invention also provides novel glycoconjugates and novel methods of synthesizing prodrugs.

  本发明提供了一种用于凝集素定向前药递送的试剂盒，包括前药和凝集素定向的糖基结合物，其中糖基结合物适应于裂解前药并释放药物。糖基结合物通常包括与结合到凝集素的碳水化合物基团偶联的酶。本发明还提供了新型糖基结合物和新型合成前药的方法。